SINGAPORE, May 08, 2025 — Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“Cuprina” or “the Company”), a company focused on creating and selling products for chronic wound care, infertility solutions, and cosmeceuticals, today announced the completion of the sale of an additional 450,000 Class A ordinary shares. This sale was due to the full exercise of the underwriter’s over-allotment option related to the company’s initial public offering (“IPO”, together with the over-allotment closing, the “Offering”). The shares were sold at the IPO price of $4.00 each, minus underwriting discounts. This brings the total gross proceeds raised by the company to $13,800,000, which includes the previously announced IPO gross proceeds of $12,000,000, before deducting underwriting discounts, commissions, and estimated offering expenses.

R. F. Lafferty & Co., Inc. (“R. F. Lafferty”) was the sole book-running manager for the Offering. Loeb & Loeb LLP, Lee & Lee, and Harney Westwood & Riegels Singapore LLP served as U.S., Singapore, and Cayman Islands legal counsel to the Company, respectively. Winston & Strawn LLP was U.S. legal counsel to R. F. Lafferty for the Offering.

The Offering is being conducted according to the Company’s registration statement on Form F-1 (File No. 333-283643), as amended, which was previously filed with the U.S. Securities and Exchange Commission (“SEC”) and declared effective on March 31, 2025. The offering is being made only through a prospectus, which is part of the registration statement. Copies of the final prospectus related to the Offering can be obtained from R. F. Lafferty & Co., Inc., 40 Wall Street, 27th Floor, New York, NY 10005; (212) 293-9090, or by email at offerings@rflafferty.com when available. The final prospectus will also be available on the SEC’s website.

Before investing, it is important to read the prospectus and other documents the Company has filed or will file with the SEC for more information about the Company and the Offering. This press release is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy these securities. Furthermore, these securities will not be offered or sold in the United States without registration or an applicable exemption from registration, nor will there be any offer, solicitation, or sale of these securities in any state or jurisdiction where such offer, solicitation, or sale would be unlawful before registration or qualification under the securities laws of that state or jurisdiction.

About Cuprina Holdings (Cayman) Limited

Based in Singapore, we are a biomedical and biotechnology company focused on creating and selling innovative products for chronic wound management and operating in the health and beauty sectors. Our biomedical research expertise allows us to find and use materials from natural sources to develop wound care products in the form of medical devices that meet international standards. For more information, please visit .

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements about future expectations, plans, and prospects, as well as other statements regarding matters that are not historical facts. These statements are considered “forward-looking statements” under the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements about expected trading commencement and closing dates. Words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” “would,” and similar expressions are used to identify forward-looking statements, although not all forward-looking statements contain these words. Actual results may differ significantly from those indicated by these forward-looking statements due to various important factors, including uncertainties related to market conditions and the completion of the public offering on the anticipated terms or at all, as well as other factors discussed in the “Risk Factors” section of the preliminary prospectus filed with the SEC. Investors are cautioned not to place undue reliance on any forward-looking statements in this press release. Any forward-looking statements in this press release are relevant only as of the date of this release, and Cuprina Holdings (Cayman) Limited specifically disclaims any obligation to update any forward-looking statement, whether due to new information, future events, or otherwise, except as required by law.

Cuprina Holdings (Cayman) Limited Investor Contact 
Investor Relations 
c/o Blk 1090 Lower Delta Road #06-08 
Singapore 169201 
+65 8512 7275 
Email: 

Investor Relations Inquiries: 
Skyline Corporate Communications Group, LLC 
Scott Powell, President 
1177 Avenue of the Americas, 5th Floor 
New York, New York 10036 
Office: (646) 893-5835 
Email: